LakeShore Biopharma Co Profit Margin

The latest profit margin for LSB is -66.9% as of March 2024. That compares with 12.79% in the prior-year period — down 623.2% year over year. That is below the sector sector average of 19.62%. Investors often review this figure alongside LakeShore Biopharma Co's historical trend and sector peers before judging valuation or financial health.

Over the past year, LSB's profit margin moved from 12.79% to -66.9% — a 623.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in LakeShore Biopharma Co's valuation or profitability profile.

Against its sector companies, LSB currently prints -66.9% for profit margin, while the sector average sits near 19.62%. That is roughly 441.0% below the sector mean. Large gaps often invite a closer look at LakeShore Biopharma Co's growth, margins, and balance sheet.

Profit Margin shows how effectively LakeShore Biopharma Co converts resources into returns. At -66.9%, LSB may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 12.79% in the prior-year period — down 623.2% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting LSB's profit margin (-66.9%), review year-over-year change from 12.79%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.